JPRN-UMIN000015847已完成2 期
A phase II, biomarker study using digital PCR method in EGFR mutated, advanced lung adenocarcinoma patients treated with afatinib. WJOG8114LTR - Liquid biopsy study of afatinib.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 57
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Incapable of oral intake 2) With intestinal paralysis, or ileus 3) Chronic diarrhea 4)Exhibiting significant interstitial pneumonitis, or pulmonary fibrosis in the chest CT 5) Uncontrolled pleural / pericardial effusion, and ascites. 6) Symptomatic brain metastasis, or meningitis carcinomatosa. 7) Prior history of thoracic radiotherapy within 4 weeks 8) Prior surgery within 4 weeks 9) Active infection 10) Positive for HBs antigen 11) With severe complication 12) Concomitant cancers within 5 years 13) History of serious drug allergies 14) Patients requiring systemic steroid medication 15) With clinically problematic, psycho-neurologic diseases 16) Pregnancy, breast feeding, or hesitation in contraception 17) Other conditions not suitable for this study
研究者
相似试验
招募中
不适用
A biomarker research of "A phase II study of second-line combination therapy with FOLFIRI plus ramucirumab in patients with RAS wild-type unresectable advanced/recurrent colorectal cancer "Colorectal cancerJPRN-UMIN000034885Japan Clinical Cancer Research Organization (JACCRO)80
进行中（未招募）
1 期
EW THERAPEUTIC INDICATION OF DECITABINE FOR THE TREATMENT OF ADVANCED, THERAPY-RESISTANT PANCREAS TUMORS WITH A SPECIFIC MOLECULAR PROFILEAdvanced (locally advanced or metastatic), pre-treated PDAC patients, progressing after at least one and no more than two lines of systemic therapy, whose tumors express a KRAS-dependency signature.MedDRA version: 21.1Level: LLTClassification code 10051971Term: Pancreatic adenocarcinomaSystem Organ Class: 100000004864EUCTR2021-002632-23-ITISTITUTI FISIOTERAPICI OSPITALIERI17
进行中（未招募）
1 期
A Phase 2 Clinical Trial in Patients with Acute Myeloid Leukemia (AML).Relapsed/Refractory Acute Myeloid Leukemia (AML) with MCL-1 dependence of =40% demonstrated by mitochondrial profiling. Newly diagnosed high-risk (NDHR) AML with MCL-1 dependence of = 40% demonstrated by mitochondrial profiling.Relapsed or primary refractory AML with varying levels of MCL 1 dependence demonstrated by mitochondrial profiling.MedDRA version: 20.0Level: LLTClassification code 10060558Term: Acute myeloid leukemia recurrentSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10000887Term: Acute myeloid leukemia in remissionSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10054294Term: Acute myeloid leukemia (in remission)System Organ Class: 100000004864EUCTR2017-001178-41-GBTolero Pharmaceuticals, Inc.104
进行中（未招募）
1 期
A Phase 2 Clinical Trial in Patients with Acute Myeloid Leukemia (AML).Relapsed/Refractory Acute Myeloid Leukemia (AML)MedDRA version: 20.0Level: LLTClassification code 10060558Term: Acute myeloid leukemia recurrentSystem Organ Class: 100000012987MedDRA version: 20.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000012984MedDRA version: 20.0Level: LLTClassification code 10000887Term: Acute myeloid leukemia in remissionSystem Organ Class: 100000012977MedDRA version: 20.0Level: LLTClassification code 10054294Term: Acute myeloid leukemia (in remission)System Organ Class: 100000012977EUCTR2017-001178-41-ESTolero Pharmaceuticals, Inc.104
进行中（未招募）
1 期
Carboplatin in mCRPCEUCTR2019-002104-40-ESCentro Nacional de Investigaciones Oncológicas (CNIO)150